Table 1 Patient characteristics

	PD	PSP	MSA	VP	DLB	UP	Disease control	Control
n	115	22	9	5	5	19	15	14
Age (y) (range)	65 (35–85)	68.2 (58–78)	60.5 (53–69)	74.8† (62–92)	74.2 (64–80)	66.6 (20–82)	67.4 (50–87)	62.6 (42–76)
Disease duration (y) (range)	10.0 (1–27)	4.8† (2–15)	6.7 (2–13)	6.6 (3–13)	6.9 (3–17)	7.9 (0.3–22)	20.8† (4–55)	–
Sex (M:F) (%)	70:30	59:41	33:67*	20:80*	80:20	53:47	53:47	50:50
L-dopa	82	52*	44*	60	80	61*	7*	0*
Dopamine agonists	60	10*	22*	0*	0*	28*	0*	0*
Amantadine	41	32	44	40	20	6*	0*	0*
Benzodiazepine	0	0	0	0	0	0	27*	0
L-dopa equivalent units (range)	619 (0–3000)	250 (0–750)	407 (0–1050)	381 (0–1100)	0	453 (0–1100)	0	0
MMSE (range)	27.7 (13–30)	25.9† (19–30)	25.8† (22–230	28.5 (27–30)	21.8† (17–28)	24.9† (0–30)	28.5 (26–30)	–
UPDRS II (range)	13.1 (2–30)	15 (6–21)	22† (10–32)	15 (0–30)	13.6 (8–24)	11.7 (0–26)	2.1† (0–8)	–
UPDRS III (range)	28.8 (7–60)	33.9 (14–60)	35 (31–42)	33 (3–55)	36.2 (24–60)	28.4 (4–74)	4.2† (0–13)	–
H&Y (range)	2.5 (1–5)	3.4† (2–4)	4† (2–5)	2.8 (1–4)	3 (2–4)	2.5 (1–5)	1 (0–2)	–
QSVHI questions
A Screen	38	0*	0*	0	80	21	0*	14
B1 Presence	46	9*	0*	20	100*	22*	11	0
B2 Passage	52	5*	0*	0*	80	28*	33	7*
B3 Illusions	47	5*	0*	20	50	11*	33	0
B Total	72	9*	0*	20	100*	37*	33	7*
C1 Formed VH	38	0*	0*	20	60	11*	0*	0
C2 VH +AH	6	0	0	0	20	0	0	0
Total VH	75	14*	0*	20	100*	47	56	7*
E1 VH + delirium	5	0	0	0	20	0	0	0
E2 Med related	2	9	0	0	0	0	33	0
Total VH - E	68	5*	0*	20	80	47*	22	7*

Medication use and QSVHI responses are expressed in per cent.
*Compared with PD, χ2 or Fisher’s exact p<0.05; †compared with PD, t test p<0.05.
AH, auditory hallucinations; DLB, dementia with Lewy bodies; H&Y, Hoehn and Yahr score; Med, medication; MMSE, Mini-Mental State Examination; MSA, multiple system atrophy; NR, not recorded; PD, Parkinson’s disease; PSP, progressive supranuclear palsy; QSVHI, Queen Square Visual Hallucination Inventory; UP, unclassifiable parkinsonism; UPDRS, Unified Parkinson’s Disease Rating Scale; VH, visual hallucinations; VP, vascular parkinsonism.